Nemorexant (Daridorexant; ACT-541468; Quviviq; ACT541468) is a novel and potent orexin receptors antagonist that has been approved in January 2022 for the treatment of Insomnia Disorder in Adult Patients. It inhibits Ox1 receptor and Ox2 receptors with IC50s of 2 nM and 3 nM, respectively. By specific binding to both orexin receptors, daridorexant inhibits the actions of the wake-promoting orexin (also called hypocretin) neuropeptides. This mechanism avoids a more widespread inhibition of neuronal pathways and associated side effects that are intrinsic to positive allosteric GABA-A receptor modulators.

纯度：≥98%

CAS：1505484-82-1